These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 1498331)

  • 21. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
    Salmon SE; Crowley JJ; Balcerzak SP; Roach RW; Taylor SA; Rivkin SE; Samlowski W
    J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
    Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
    Cavo M; Zamagni E; Tosi P; Tacchetti P; Cellini C; Cangini D; de Vivo A; Testoni N; Nicci C; Terragna C; Grafone T; Perrone G; Ceccolini M; Tura S; Baccarani M;
    Blood; 2005 Jul; 106(1):35-9. PubMed ID: 15761019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).
    Monconduit M; Menard JF; Michaux JL; Le Loet X; Bernard JF; Grosbois B; Pollet JP; Azais I; Laporte JP; Doyen C
    Br J Haematol; 1992 Feb; 80(2):199-204. PubMed ID: 1550777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
    Berenson JR; Crowley JJ; Grogan TM; Zangmeister J; Briggs AD; Mills GM; Barlogie B; Salmon SE
    Blood; 2002 May; 99(9):3163-8. PubMed ID: 11964279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
    Teng HW; Teng CJ; Wang WS; Chen PM; Chiou TJ; Hsu HC; Liu JH; Yen CC; Hsiao LT; Yang MH; Chao TC; Yang YH; Gau JP
    Am J Hematol; 2010 Oct; 85(10):812-5. PubMed ID: 20734459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy of primary resistant and relapsed multiple myeloma.
    Barlogie B; Alexanian R
    Onkologie; 1986 Aug; 9(4):210-4. PubMed ID: 3531948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
    Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou M; Mitsouli Ch; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A;
    Ann Oncol; 2004 Jan; 15(1):134-8. PubMed ID: 14679133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VAD followed by VMCP: an alternative regimen for multiple myeloma.
    Wadhwa J; Kumar L; Kochupillai V
    Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
    Mineur P; Ménard JF; Le Loët X; Bernard JF; Grosbois B; Pollet JP; Azais I; Laporte JP; Doyen C; De Gramont A; Wetterwald M; Euller-Ziegler L; Peny AM; Monconduit M; Michaux JL
    Br J Haematol; 1998 Nov; 103(2):512-7. PubMed ID: 9827927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
    Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
    Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
    [No Abstract]   [Full Text] [Related]  

  • 35. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; von Broen IM; Fischer JT; Gramatzki M
    Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
    Segeren CM; Sonneveld P; van der Holt B; Baars JW; Biesma DH; Cornellissen JJ; Croockewit AJ; Dekker AW; Fibbe WE; Löwenberg B; van Marwijk Kooy M; van Oers MH; Richel DJ; Schouten HC; Vellenga E; Verhoef GE; Wijermans PW; Wittebol S; Lokhorst HM
    Br J Haematol; 1999 Apr; 105(1):127-30. PubMed ID: 10233375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma.
    Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR
    Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma.
    Porter CA; Rifkin RM
    Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S150-5. PubMed ID: 17562253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.